FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149177103> ?p ?o ?g. }

• W2149177103 endingPage "749" @default.
• W2149177103 startingPage "743" @default.
• W2149177103 abstract "Abstract Purpose: A major mechanism of resistance to chlorethylnitrosureas and methylating agents involves the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). We sought to determine the dose of oral 6-(4-bromo-2-thienyl) methoxy purin-2-amine (lomeguatrib), a pseudosubstrate inactivator of MGMT, required to render active protein undetectable 12 hours after dosing in prostate, primary central nervous system (CNS), and colorectal cancer patients. Experimental Design: Lomeguatrib was administered orally as a single dose (20-160 mg) ∼12 hours before tumor resection. Dose escalation was projected to continue until grade 2 toxicity or until complete inactivation of tumor MGMT was encountered. Total MGMT protein levels were quantified by ELISA, and active protein levels were quantified by biochemical assay. MGMT promoter methylation was determined in glioblastoma DNA by methylation-specific PCR. Results: Thirty-seven patients were dosed with lomeguatrib, and 32 informative tumor samples were obtained. Mean total MGMT level varied between tumor types: 554 ± 404 fmol/mg protein (±SD) for prostate cancer, 87.4 ± 40.3 fmol/mg protein for CNS tumors, and 244 ± 181 fmol/mg protein for colorectal cancer. MGMT promoter hypermethylation did not correlate with total protein expression. Consistent total MGMT inactivation required 120 mg of lomeguatrib in prostate and colorectal cancers. Complete consistent inactivation in CNS tumors was observed only at the highest dose of lomeguatrib (160 mg). Conclusions: Total MGMT inactivation can be achieved in prostate, primary CNS, and colorectal cancers with a single administration of 120 or 160 mg lomeguatrib. The dose needed did not correlate with mean total MGMT protein concentrations. One hundred twenty to 160 mg/d of lomeguatrib should be administered to achieve total MGMT inactivation in future studies. Clin Cancer Res; 16(2); 743–9" @default.
• W2149177103 created "2016-06-24" @default.
• W2149177103 creator A5002020644 @default.
• W2149177103 creator A5003099467 @default.
• W2149177103 creator A5003827407 @default.
• W2149177103 creator A5020185558 @default.
• W2149177103 creator A5020424520 @default.
• W2149177103 creator A5022006253 @default.
• W2149177103 creator A5051430596 @default.
• W2149177103 creator A5051791517 @default.
• W2149177103 creator A5052834238 @default.
• W2149177103 creator A5063209940 @default.
• W2149177103 creator A5064932321 @default.
• W2149177103 creator A5077801086 @default.
• W2149177103 creator A5086219801 @default.
• W2149177103 date "2010-01-14" @default.
• W2149177103 modified "2023-10-12" @default.
• W2149177103 title "Tumor <i>O</i>6-methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib" @default.
• W2149177103 cites W1988299559 @default.
• W2149177103 cites W1998299598 @default.
• W2149177103 cites W2028056960 @default.
• W2149177103 cites W2046938856 @default.
• W2149177103 cites W2071248985 @default.
• W2149177103 cites W2095443177 @default.
• W2149177103 cites W2105100844 @default.
• W2149177103 cites W2114124586 @default.
• W2149177103 cites W2145047381 @default.
• W2149177103 cites W2165770167 @default.
• W2149177103 cites W2167895705 @default.
• W2149177103 cites W4235858387 @default.
• W2149177103 cites W4242475406 @default.
• W2149177103 doi "https://doi.org/10.1158/1078-0432.ccr-09-1389" @default.
• W2149177103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2807621" @default.
• W2149177103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20068091" @default.
• W2149177103 hasPublicationYear "2010" @default.
• W2149177103 type Work @default.
• W2149177103 sameAs 2149177103 @default.
• W2149177103 citedByCount "31" @default.
• W2149177103 countsByYear W21491771032012 @default.
• W2149177103 countsByYear W21491771032013 @default.
• W2149177103 countsByYear W21491771032014 @default.
• W2149177103 countsByYear W21491771032015 @default.
• W2149177103 countsByYear W21491771032016 @default.
• W2149177103 countsByYear W21491771032018 @default.
• W2149177103 countsByYear W21491771032020 @default.
• W2149177103 countsByYear W21491771032021 @default.
• W2149177103 countsByYear W21491771032023 @default.
• W2149177103 crossrefType "journal-article" @default.
• W2149177103 hasAuthorship W2149177103A5002020644 @default.
• W2149177103 hasAuthorship W2149177103A5003099467 @default.
• W2149177103 hasAuthorship W2149177103A5003827407 @default.
• W2149177103 hasAuthorship W2149177103A5020185558 @default.
• W2149177103 hasAuthorship W2149177103A5020424520 @default.
• W2149177103 hasAuthorship W2149177103A5022006253 @default.
• W2149177103 hasAuthorship W2149177103A5051430596 @default.
• W2149177103 hasAuthorship W2149177103A5051791517 @default.
• W2149177103 hasAuthorship W2149177103A5052834238 @default.
• W2149177103 hasAuthorship W2149177103A5063209940 @default.
• W2149177103 hasAuthorship W2149177103A5064932321 @default.
• W2149177103 hasAuthorship W2149177103A5077801086 @default.
• W2149177103 hasAuthorship W2149177103A5086219801 @default.
• W2149177103 hasBestOaLocation W21491771031 @default.
• W2149177103 hasConcept C104317684 @default.
• W2149177103 hasConcept C121608353 @default.
• W2149177103 hasConcept C126322002 @default.
• W2149177103 hasConcept C150194340 @default.
• W2149177103 hasConcept C190727270 @default.
• W2149177103 hasConcept C2776235491 @default.
• W2149177103 hasConcept C2779979206 @default.
• W2149177103 hasConcept C2780192828 @default.
• W2149177103 hasConcept C33288867 @default.
• W2149177103 hasConcept C502942594 @default.
• W2149177103 hasConcept C526805850 @default.
• W2149177103 hasConcept C552990157 @default.
• W2149177103 hasConcept C55493867 @default.
• W2149177103 hasConcept C71924100 @default.
• W2149177103 hasConcept C86803240 @default.
• W2149177103 hasConcept C91965660 @default.
• W2149177103 hasConceptScore W2149177103C104317684 @default.
• W2149177103 hasConceptScore W2149177103C121608353 @default.
• W2149177103 hasConceptScore W2149177103C126322002 @default.
• W2149177103 hasConceptScore W2149177103C150194340 @default.
• W2149177103 hasConceptScore W2149177103C190727270 @default.
• W2149177103 hasConceptScore W2149177103C2776235491 @default.
• W2149177103 hasConceptScore W2149177103C2779979206 @default.
• W2149177103 hasConceptScore W2149177103C2780192828 @default.
• W2149177103 hasConceptScore W2149177103C33288867 @default.
• W2149177103 hasConceptScore W2149177103C502942594 @default.
• W2149177103 hasConceptScore W2149177103C526805850 @default.
• W2149177103 hasConceptScore W2149177103C552990157 @default.
• W2149177103 hasConceptScore W2149177103C55493867 @default.
• W2149177103 hasConceptScore W2149177103C71924100 @default.
• W2149177103 hasConceptScore W2149177103C86803240 @default.
• W2149177103 hasConceptScore W2149177103C91965660 @default.
• W2149177103 hasIssue "2" @default.
• W2149177103 hasLocation W21491771031 @default.
• W2149177103 hasLocation W21491771032 @default.
• W2149177103 hasLocation W21491771033 @default.

• next